CERo Therapeutics Holdings (CERO) Income Statement
CERo Therapeutics Holdings Income Statement
Last quarter (Q2 2026), CERo Therapeutics Holdings's total revenue was $0.00. In Q2, CERo Therapeutics Holdings's net income was $-1.03M. See CERo Therapeutics Holdings’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | |
| $ -1.09M | $ -1.16M | $ -1.12M | $ 0.00 | $ 0.00 | |
| $ 17.38M | $ 15.30M | $ 2.93M | $ 2.91M | $ 431.50K | |
| Depreciation and Amortization | $ 1.09M | $ 1.16M | $ 1.12M | $ 1.07M | $ 735.47K |
| $ -17.38M | $ -6.57M | $ -1.32M | $ -1.83M | $ 403.06K | |
| $ -18.46M | $ -15.30M | $ -2.93M | $ -2.91M | $ -332.03K | |
| $ -1.46M | $ 7.57M | $ 491.57K | $ 2.84M | $ -385.00 | |
| $ -19.92M | $ -7.73M | $ -2.44M | $ -68.58K | $ -332.42K | |
| $ -19.92M | $ -7.73M | $ -2.54K | $ -667.74K | $ -315.55K | |
| Per Share Metrics | |||||
| Basic EPS | $ -22.58 | $ -6.87 | $ -2497.20 | $ -19.73 | $ -2.75 |
| Diluted EPS | $ -22.58 | $ -6.87 | $ -2497.20 | $ -19.73 | $ -2.75 |
| Weighted Average Shares Outstanding | 4.23M | 120.79K | 7.35K | 7.35K | 7.35K |
| Weighted Average Shares Outstanding (Diluted) | 4.23M | 120.79K | 7.35K | 7.35K | 7.35K |
Currency in USD
